The Uromigos

Episode 436: The History of IO in RCC - Part 2

Episode 435: The History of IO in RCC - Part 1

Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC

Episode 433: Uromigos Japan - 改訂版ASCO mCRPCガイドライン

Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap

Episode 432: Recap of the ASCO Rapid Oral RCC/Bladder Session

Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials

Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?

Episode 429: ASCO2025レポート

Episode 428: ASCO 2025 Recap

Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)

Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC

Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI

Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session

Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC

Episode 422: ACSO 2025 - ctDNA data from NIAGARA

Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer

Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer

Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study

Episode 418: ASCO 2025 - Biomarkers in RCC

Episode 417: ASCO25 GUの注目演題について3人でDiscussion！！

Episode 416: ASCO 2025 Preview

Episode 415: Uromigos Score 前立腺がん編

Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas

Episode 413: The Uromigos Score for Advanced Prostate Cancer

Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC

Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1

Episode 411: Live from EIKCS in Amsterdam - RCC Highlights

Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC

Episode 408: Uromigos Japan - European Delphi Study of mRCCについてdiscussion

Episode 407: Drug Development in China: Part 2 of 2

Episode 406: Drug Development in China: Part 1 of 2

Episode 405: The Good News About Cancer podcast

Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands

Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands

Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales

Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands

Episode 400: The Uromigos Score for Urothelial Cancer

Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?

Episode 398: Reflections on the Felix Feng Symposium at ASCO GU

Episode 397: APCCC Diagnostics Conference recap

Episode 396: Uromigos Japan - 激論 @JSMO25

Episode 395: Uromigos Japan: ASCO GU 2025のレビュー

Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025

Episode 393: ASCO GU 2025 Review Podcast

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC

Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214

Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update

Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer

Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results